SCHEMBL15218404

SCHEMBL15218404

CCCC(C)NS(C)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
CA2 P00918 4/20 0.48
CA12 O43570 3/20 0.48
CA9 Q16790 1/20 0.48
ALDH1A1 P00352 5/20 0.38
ACACB O00763 1/20 0.36
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CA1 P00915 3/20 0.32
CA7 P43166 2/20 0.32
CA14 Q9ULX7 2/20 0.32
HCAR3 P49019 1/20 0.32
HDAC7 Q8WUI4 2/20 0.32
HDAC8 Q9BY41 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21789783 0.86 ADH1B (0.41) SMN1; SMN2CA2CA12CA9ALDH1A1
SCHEMBL9888689 0.86 ADH1B (0.41) SMN1; SMN2CA2CA12CA9ALDH1A1
SCHEMBL15218449 0.84 ADH1B (0.48) SMN1; SMN2CA2CA12CA9ALDH1A1
SCHEMBL24665666 0.82 ADH1B (0.52) SMN1; SMN2CA2CA12CA9CA1
SCHEMBL11326311 0.82 ADH1B (0.52) SMN1; SMN2CA2CA12CA9CA1
SCHEMBL5254185 0.82 SMN1; SMN2 (0.52) SMN1; SMN2CA2CA12CA9ALDH1A1
SCHEMBL15218403 0.80 ALDH1A1 (0.41) SMN1; SMN2CA2CA12CA9ALDH1A1
SCHEMBL13275294 0.79
SCHEMBL9888693 0.79
SCHEMBL18434131 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210177804-A1 DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE AXOVANT SCIENCES GMBH (CH) 2021-06-17 US disclosed
US-20160313639-A1 PHOTOSENSITIVE RESIN COMPOSITION, PIXEL LAYER, PROTECTIVE FILM, SPACER, THIN-FILM TRANSISTOR, COLOR FILTER, AND LIQUID CRYSTAL DISPLAY APPARATUS CHI MEI CORPORATION (TW) 2016-10-27 US disclosed
US-20160313639-A1 PHOTOSENSITIVE RESIN COMPOSITION, PIXEL LAYER, PROTECTIVE FILM, SPACER, THIN-FILM TRANSISTOR, COLOR FILTER, AND LIQUID CRYSTAL DISPLAY APPARATUS CHI MEI CORPORATION (TW) 2016-10-27 US disclosed
CN-104837843-B Imidazopyridazine derivant as GABAA receptor modulators 辉瑞有限公司 2016-08-31 CN disclosed
US-9274419-B2 Blue photosensitive resin composition for color filter and application thereof CHI MEI CORPORATION (TW) 2016-03-01 US disclosed
US-9274419-B2 Blue photosensitive resin composition for color filter and application thereof CHI MEI CORPORATION (TW) 2016-03-01 US disclosed
US-20150268554-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2015-09-24 US disclosed
US-20150268554-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2015-09-24 US disclosed
CN-104837843-A Imidazopyridazine derivatives as GABAA receptor modulators PFIZER 2015-08-12 CN disclosed
US-9086532-B2 Blue photosensitive resin composition for color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-21 US disclosed
US-9081142-B2 Photosensitive resin composition for a color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-14 US disclosed
US-9081142-B2 Photosensitive resin composition for a color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-14 US disclosed
US-20150042931-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2015-02-12 US disclosed
US-20150042931-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2015-02-12 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20130222738-A1 COLOR LIQUID CRYSTAL DISPLAY DEVICE CHI MEI CORPORATION (TW) 2013-08-29 US disclosed
US-20130222738-A1 COLOR LIQUID CRYSTAL DISPLAY DEVICE CHI MEI CORPORATION (TW) 2013-08-29 US disclosed
CN-101420941-A Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies ARENA PHARM INC (US) 2009-04-29 CN disclosed
CN-101332303-A Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level ARENA PHARM INC (US) 2008-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177804-A1 DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE HTR2A, HTR5A, HTR1A SMN1; SMN2 1508/4885CA2 4789/4885CA12 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.